These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17151533)

  • 1. [Acceptability of intrauterine levonorgestrel delivery system (Mirena 52mg) after estrogen-progesterone oral contraception: results of a prospective multicentric study of 211 patients aged 25-35 years].
    Collinet P; Nayama M; Cosson M
    J Gynecol Obstet Biol Reprod (Paris); 2006 Dec; 35(8 Pt 1):778-84. PubMed ID: 17151533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives.
    French RS; Cowan FM; Mansour D; Higgins JP; Robinson A; Procter T; Morris S; Guillebaud J
    BJOG; 2000 Oct; 107(10):1218-25. PubMed ID: 11028571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contraception and treatment in the perimenopause with a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: an extended pilot study.
    Wildemeersch D; Schacht E; Wildemeersch P
    Contraception; 2002 Aug; 66(2):93-9. PubMed ID: 12204781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years.
    Dubuisson JB; Mugnier E
    Contraception; 2002 Aug; 66(2):121-8. PubMed ID: 12204786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception.
    Rose S; Chaudhari A; Peterson CM
    Adv Drug Deliv Rev; 2009 Aug; 61(10):808-12. PubMed ID: 19445984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
    Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study.
    Baldaszti E; Wimmer-Puchinger B; Löschke K
    Contraception; 2003 Feb; 67(2):87-91. PubMed ID: 12586318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study.
    Sivin I; el Mahgoub S; McCarthy T; Mishell DR; Shoupe D; Alvarez F; Brache V; Jimenez E; Diaz J; Faundes A
    Contraception; 1990 Oct; 42(4):361-78. PubMed ID: 2124179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study.
    Luukkainen T; Allonen H; Haukkamaa M; Holma P; Pyörälä T; Terho J; Toivonen J; Batar I; Lampe L; Andersson K
    Contraception; 1987 Aug; 36(2):169-79. PubMed ID: 3123132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who can afford a Mirena® for contraception?
    Murray C; Roke C
    J Prim Health Care; 2018 Oct; 10(3):201-206. PubMed ID: 31039933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
    Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
    Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
    Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
    Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
    Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
    Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use.
    Gemzell-Danielsson K; Apter D; Dermout S; Faustmann T; Rosen K; Schmelter T; Merz M; Nelson A
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():22-28. PubMed ID: 27930941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
    Luukkainen T; Toivonen J
    Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding.
    Lethaby AE; Cooke I; Rees M
    Cochrane Database Syst Rev; 2000; (2):CD002126. PubMed ID: 10796865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial.
    Kakaire O; Tumwesigye NM; Byamugisha JK; Gemzell-Danielsson K
    Eur J Contracept Reprod Health Care; 2016 Jun; 21(3):220-6. PubMed ID: 26895345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.